A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Cyclophosphamide|DRUG: Trastuzumab|DRUG: Pertuzumab|BIOLOGICAL: NK cells|DRUG: Interleukin-2
Sponsor: Vall d'Hebron Institute of Oncology
Collaborators: Clinica Universidad de Navarra, Universidad de Navarra|Puerta de Hierro University Hospital|Hospital del Mar|Banc de Sang i Teixits